Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability,... Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. Mehr anzeigen
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half...
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA...
On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0473 | 3.6309203961 | 1.3027 | 1.45 | 1.26 | 572708 | 1.31913797 | CS |
| 4 | -2.03 | -60.0591715976 | 3.38 | 4.0695 | 1.225 | 770999 | 2.15982175 | CS |
| 12 | -2.07 | -60.5263157895 | 3.42 | 4.0695 | 1.225 | 312659 | 2.42533936 | CS |
| 26 | -2.03 | -60.0591715976 | 3.38 | 4.29 | 1.225 | 209944 | 2.73136758 | CS |
| 52 | -5.26 | -79.5763993949 | 6.61 | 8.49 | 1.225 | 204965 | 3.79551696 | CS |
| 156 | -20.96 | -93.9489018377 | 22.31 | 22.63 | 1.225 | 242749 | 9.33205314 | CS |
| 260 | -30.7 | -95.7878315133 | 32.05 | 46.44 | 1.225 | 212351 | 14.24080925 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
